サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541305

急性骨髄性白血病治療薬市場レポート：治療タイプ、薬剤タイプ、投与経路、地域別、2024年～2032年

Acute Myeloid Leukemia Therapeutics Market Report by Treatment Type, Drug Type, Route of Administration, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 141 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
急性骨髄性白血病治療薬市場レポート：治療タイプ、薬剤タイプ、投与経路、地域別、2024年～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 141 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

急性骨髄性白血病治療薬の世界市場規模は、2023年に12億950万米ドルに達しました。今後、IMARC Groupは、市場が2032年までに32億360万米ドルに達し、2024年から2032年の間に11.1％の成長率（CAGR）を示すと予測しています。

急性骨髄性白血病（AML）は、異常細胞が急速に増殖するクローン性の悪性腫瘍です。主に骨髄と白血球（WBC）に影響を及ぼし、皮膚の変色、息苦しさ、疲労、高体温、体重減少、歯茎の出血、鼻血が特徴です。一般的に使用されるAML治療法には、化学療法、免疫療法、分子標的療法、ホルモン療法、外科手術などがあります。これらの治療法は通常、有効性を高め、合併症を最小限に抑え、身体の免疫系を強化するために幹細胞移植と併用されます。

世界中で白血病の有病率が増加していることは、市場の成長を促進する重要な要因の一つです。さらに、このような疾患に罹患しやすい老年人口が増加していることも、市場の成長を後押ししています。AMLは主に体内の遺伝子変異によって引き起こされ、血球産生レベルに影響を与えます。これに伴い、併用療法や標的療法が広く採用され、がん治療に利用可能な代替療法に関する認識が高まっていることも、市場成長に好影響を与えています。さらに、改良された免疫毒素、アルキル化剤、モノクローナル抗体、多剤耐性モジュレーターの登場も、成長を促す大きな要因です。これらの治療薬は、治療効果の延長、より高い有効性、白血病細胞の早期かつ正確な同定、がん再発の可能性の減少をもたらします。腫瘍学分野における広範な研究開発（R&D）活動や既存のヘルスケアインフラの大幅な改善など、その他の要因も市場をさらに牽引すると予想されます。

本レポートで扱う主な質問

  • 世界の急性骨髄性白血病治療薬の市場はこれまでどのように推移し、今後どのように推移していくのか？
  • COVID-19は世界の急性骨髄性白血病治療薬の市場にどのような影響を与えたか？
  • 主要地域市場とは？
  • 治療タイプ別の市場内訳は？
  • 薬剤タイプ別の市場内訳は？
  • 投与経路に基づく市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界の急性骨髄性白血病治療薬の市場の構造と主要プレーヤーは？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の急性骨髄性白血病治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療タイプ別

  • シタラビン
    • 市場動向
    • 市場予測
  • アントラサイクリン系薬剤
    • 市場動向
    • 市場予測
  • アルキル化剤
    • 市場動向
    • 市場予測
  • 代謝阻害物質
    • 市場動向
    • 市場予測
  • チロシンキナーゼ阻害剤
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：薬剤タイプ別

  • 低分子医薬品
    • 市場動向
    • 市場予測
  • バイオ医薬品
    • 市場動向
    • 市場予測

第8章 市場内訳：投与経路別

  • 経口
    • 市場動向
    • 市場予測
  • 注射剤
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbvie Inc.
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Celgene
    • Roche Holding AG
    • Gilead Sciences Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
図表

List of Figures

  • Figure 1: Global: Acute Myeloid Leukemia Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Treatment Type (in %), 2023
  • Figure 5: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Drug Type (in %), 2023
  • Figure 6: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Route of Administration (in %), 2023
  • Figure 7: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Acute Myeloid Leukemia Therapeutics (Cytarabine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Acute Myeloid Leukemia Therapeutics (Cytarabine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Acute Myeloid Leukemia Therapeutics (Anthracycline Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Acute Myeloid Leukemia Therapeutics (Anthracycline Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Acute Myeloid Leukemia Therapeutics (Alkylating Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Acute Myeloid Leukemia Therapeutics (Alkylating Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Acute Myeloid Leukemia Therapeutics (Anti-Metabolites) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Acute Myeloid Leukemia Therapeutics (Anti-Metabolites) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Acute Myeloid Leukemia Therapeutics (Tyrosine Kinase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Acute Myeloid Leukemia Therapeutics (Tyrosine Kinase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Acute Myeloid Leukemia Therapeutics (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Acute Myeloid Leukemia Therapeutics (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Acute Myeloid Leukemia Therapeutics (Small Molecule Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Acute Myeloid Leukemia Therapeutics (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Acute Myeloid Leukemia Therapeutics (Biopharmaceuticals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Acute Myeloid Leukemia Therapeutics (Biopharmaceuticals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Acute Myeloid Leukemia Therapeutics (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Acute Myeloid Leukemia Therapeutics (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Acute Myeloid Leukemia Therapeutics (Injectables) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Acute Myeloid Leukemia Therapeutics (Injectables) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market: Breakup by Country (in %), 2023
  • Figure 77: Global: Acute Myeloid Leukemia Therapeutics Industry: SWOT Analysis
  • Figure 78: Global: Acute Myeloid Leukemia Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Acute Myeloid Leukemia Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Acute Myeloid Leukemia Therapeutics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 3: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 4: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 5: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Acute Myeloid Leukemia Therapeutics Market: Competitive Structure
  • Table 7: Global: Acute Myeloid Leukemia Therapeutics Market: Key Players
目次
Product Code: SR112024A3129

The global acute myeloid leukemia therapeutics market size reached US$ 1,209.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 3,203.6 Million by 2032, exhibiting a growth rate (CAGR) of 11.1% during 2024-2032.

Acute myeloid leukemia (AML) refers to a clonal malignancy leading to the rapid growth of abnormal cells. It primarily impacts the bone marrow and white blood cells (WBCs) and is characterized by the discoloration of skin, breathlessness, fatigue, high body temperatures, weight loss, bleeding gums and nosebleeds. Some of the commonly used AML therapies include chemo-, immuno-, targeted- and hormonal therapies and surgical procedures. These therapeutics are usually combined with stem cell transplants to increase the efficacy, minimize complications and strengthen the immune system of the body.

The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such disorders, is also driving the market growth. AML is primarily caused by genetic mutations in the body that impacts the levels of blood cell production. In line with this, the widespread adoption of combination and targeted therapies and increasing awareness regarding the available alternatives for cancer treatment are also favoring the market growth. Additionally, the advent of improved immunotoxins, alkylating agents, monoclonal antibodies and multidrug-resistant modulators is another major growth-inducing factor. These therapeutics offer prolonged results, higher efficacy, early and accurate identification of leukemia cells and reduced chances of cancer relapse. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with significant improvements in the existing healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global acute myeloid leukemia therapeutics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on treatment type, drug type and route of administration.

Breakup by Treatment Type:

Cytarabine

Anthracycline Drugs

Alkylating Agents

Anti-Metabolites

Tyrosine Kinase Inhibitors

Others

Breakup by Drug Type:

Small Molecule Drugs

Biopharmaceuticals

Breakup by Route of Administration:

Oral

Injectables

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene, Roche Holding AG, Gilead Sciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report:

  • How has the global acute myeloid leukemia therapeutics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global acute myeloid leukemia therapeutics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global acute myeloid leukemia therapeutics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Acute Myeloid Leukemia Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Cytarabine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Anthracycline Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alkylating Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Anti-Metabolites
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Tyrosine Kinase Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Small Molecule Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biopharmaceuticals
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectables
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbvie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Celgene
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Roche Holding AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Gilead Sciences Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Novartis AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Takeda Pharmaceutical Company Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis